EFFECTS OF COST-SHARING FOR POST ACUTE CARE: EVIDENCE FROM MEDICARE ADVANTAGE

费用分摊对急性后期护理的影响:来自医疗保险优势的证据

基本信息

  • 批准号:
    8618228
  • 负责人:
  • 金额:
    $ 16.41万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2007
  • 资助国家:
    美国
  • 起止时间:
    2007-09-15 至
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY (See instructions): Medicare spending on post-acute care has exploded in the past decade, catalyzing intense policy interest in strategies to reduce post-acute expenditures without harming health or increasing the offsetting costs of other health services. Under the traditional Medicare benefit design, the first 20 days of skilled nursing facility care and all episodes of home care are provided free (i.e. without a copayment), raising concerns about patients' incentives to overuse these services, even when they are of little or no value. To address this concern President Obama, the Medicare Payment Advisory Commission, and the Simpson-Bowles deficit reduction committee have all expressed support for the imposition of a copayment for the use of post-acute care. Yet, there is no empirical evidence base to predict, the impact of such policies. The objective of this proposal is to evaluate the impact of changes in cost-sharing on the use and outcomes of post-acute care using a quasi-experimental research design and a national sample of Medicare enrollees in managed care plans. The central hypotheses of the proposed research, which is based on the results of an extensive series of preliminary studies, are that copayments will sharply reduce the use of post-acute care, induce shifts to other post-acute services with lower out-of-pocket costs, drive hospitalized beneficiaries out of managed care plans into the fee-for-service system, and increase hospital length of stay and the probability of readmission. Our expectations are that this project will provide rigorous estimates of the response of Medicare beneficiaries to post-acute copayments and contribute significantly to our understanding of the effect of cost-sharing among the elderly, who were excluded from the landmark RAND Health Insurance Experiment conducted in the 1970's: Finally, this research can inform optimal Medicare benefit policies that promote better health outcomes and the appropriate use of post-acute services while minimizing negative unintended consequences for frail elderly and the Medicare program budget.
项目概述(见说明):

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

AMAL N. TRIVEDI其他文献

AMAL N. TRIVEDI的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('AMAL N. TRIVEDI', 18)}}的其他基金

Impact of COVID-era Disrupted Care on Disparities in Outcomes among Veterans with Kidney Failure
新冠病毒时代护理中断对肾功能衰竭退伍军人结果差异的影响
  • 批准号:
    10755601
  • 财政年份:
    2022
  • 资助金额:
    $ 16.41万
  • 项目类别:
Impact of COVID-era Disrupted Care on Disparities in Outcomes among Veterans with Kidney Failure
新冠病毒时代护理中断对肾功能衰竭退伍军人结果差异的影响
  • 批准号:
    10424969
  • 财政年份:
    2022
  • 资助金额:
    $ 16.41万
  • 项目类别:
Effects of Expanding Medicare Advantage Enrollment toPersons with End-stage Renal Disease
扩大医疗保险优惠覆盖范围对终末期肾病患者的影响
  • 批准号:
    10435533
  • 财政年份:
    2021
  • 资助金额:
    $ 16.41万
  • 项目类别:
Effects of Expanding Medicare Advantage Enrollment toPersons with End-stage Renal Disease
扩大医疗保险优惠覆盖范围对终末期肾病患者的影响
  • 批准号:
    10275943
  • 财政年份:
    2021
  • 资助金额:
    $ 16.41万
  • 项目类别:
Effects of Expanding Medicare Advantage Enrollment toPersons with End-stage Renal Disease
扩大医疗保险优惠覆盖范围对终末期肾病患者的影响
  • 批准号:
    10609923
  • 财政年份:
    2021
  • 资助金额:
    $ 16.41万
  • 项目类别:
Infection Control Measures in Dialysis Facilities after COVID-19: Disparities in Adoption and Impact on Hospitalization and Mortality
COVID-19 后透析设施的感染控制措施:采用差异以及对住院和死亡率的影响
  • 批准号:
    10193135
  • 财政年份:
    2021
  • 资助金额:
    $ 16.41万
  • 项目类别:
Infection Control Measures in Dialysis Facilities after COVID-19: Disparities in Adoption and Impact on Hospitalization and Mortality
COVID-19 后透析设施的感染控制措施:采用差异以及对住院和死亡率的影响
  • 批准号:
    10321302
  • 财政年份:
    2021
  • 资助金额:
    $ 16.41万
  • 项目类别:
Impact of VA Disability and Health Benefits on Long-Term Diabetes Outcomes among Vietnam-Era Veterans
退伍军人事务部残疾和健康福利对越战时期退伍军人长期糖尿病结局的影响
  • 批准号:
    10051323
  • 财政年份:
    2018
  • 资助金额:
    $ 16.41万
  • 项目类别:
Medicaid Expansion, Coverage Loss, and Disparities in Kidney Health in the COVID-19 Era
COVID-19 时代的医疗补助范围扩大、覆盖范围缩小以及肾脏健康方面的差异
  • 批准号:
    10447753
  • 财政年份:
    2017
  • 资助金额:
    $ 16.41万
  • 项目类别:
Risk-Adjusting Hospital Outcomes for Veteran's Socioeconomic Status
根据退伍军人的社会经济地位调整医院结果的风险
  • 批准号:
    9188841
  • 财政年份:
    2017
  • 资助金额:
    $ 16.41万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 16.41万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 16.41万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 16.41万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 16.41万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 16.41万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 16.41万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 16.41万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 16.41万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 16.41万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 16.41万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了